Phase II trial of oral altretamine for relapsed ovarian carcinoma: Evaluation of defining response by serum CA125

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 172-176

  Rustin, G J ^a   Nelstrop, A E ^a   Crawford, M ^a   Ledermann, J ^a   Lambert, H E ^a   Coleman, R ^a   Johnson, J ^a   Evans, H ^a   Brown, S ^a   Oster, W ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

EID: 0031028270     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.172     Document Type: Article

References (18)

1. Lambert HE, Rustin GJS, Gregory WM, et al: A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: A North Thames Group Study. J Clin Oncol 11:440-448, 1993
2. Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393, 1991
3. Blackledge G, Lawton F, Redman C, et al: Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design of phase II trials. Br J Cancer 59:650-653, 1989
4. Rhoda-Lee C, Faulds D: Altretamine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in cancer chemotherapy. Drugs 49:932-953, 1995
5. Hainsworth JD, Jones HW, Burnett LS, et al: The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: A comparison of hexamethylmelamine, cyclophosphamide, doxorubicin and cisplatin (h-cap) versus cyclophosphamide, doxorubicin and cisplatin (cap). Am J Clin Oncol 13:410-415, 1990
6. Bruckner HW, Cohen C, Mandeli J, et al: Hexamethylmelamine for the treatment of ovarian cancer: The Mount Sinai experience. Cancer Treat Rev 18:57-65, 1991 (suppl A)
7. Edmondson JH, Wieland HS, McCormack GW: Role of hexamethylmelamine in the treatment of ovarian cancer: Where is the needle in the haystack? J Natl Cancer Inst 80:1172-1173, 1988
8. Stehman FB, Ehrlich CE, Callangan RN: Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy. Gynecol Oncol 17:189-195, 1984
9. Field AL, Schink C, Miller DS, et al: Oral hexamethylmelamine: An effective salvage therapy for recurrent ovarian cancer. Proceedings of the Thirteenth World Congress of Gynaecology and Obstetrics, Singapore, 1991 (abstr 2048)
10. Vergote I, Himmelmann A, Frankendal B: Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol Oncol 47:282-286, 1992
11. Rustin GJS, Nelstrop AE, McClean P, et al: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA125. J Clin Oncol 14:1545-1551, 1996
12. Rustin GJS, Nelstrop AE, Tuxen MK, et al: Defining progression of ovarian carcinoma during follow-up according to CA125: A North Thames Ovary Group Study. Ann Oncol 7:361-364, 1996
13. Van Oosterom A: Tumour eligibility and response criteria for phase II and III studies and (sub) acute toxicity grading in EORTC Data Centre Procedures Manual. Brussels, Belgium, EORTC, 1992, pp 119-133
14. Gore ME, Levy V, Rustin GJS, et al: Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: The UK and Eire experience. Br J Cancer 72:1016-1019, 1995
15. Thigpen JT, Blessing JA, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 12:1748-1753, 1994
16. Piccart MJ, Gore M, ten Bokkel Huinink W, et al: Docetaxel: An active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87:676-681, 1995
17. Schink JC, Harris LS, Grosen ER, et al: Altretamine (Hexalen) an effective salvage chemotherapy after paclitaxel (Taxol) in women with recurrent resistant ovarian cancer. Proc Am Soc Clin Oncol 14:275, 1995 (abstr 770)
18. Piccart MJ, Rustin GJS, Gore M, et al: Docetaxel (Taxotere): A new active agent by WHO and CA125 response criteria, in platinum-pretreated advanced epithelial ovarian cancer, in Sharp F, Blackett A, Leake R, et al (eds): Ovarian Cancer (vol 4). London, United Kingdom, Chapman & Hall, 1996, pp 153-163